Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin) (inc rev TA142) [ID541]

Anticipated publication date:

Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142)
 
Status
In development
Anticipated publication date
August 2014
Process
MTA
Topic area
  • Blood and immune system
  • Endocrine, nutritional and metabolic

Provisional Schedule

Closing date for invited submissions / evidence submission: 25 September 2013
1st appraisal committee meeting: 19 March 2014
2nd appraisal committee meeting: 21 May 2014

Project Team

Executive Lead: Carole Longson
Technical Lead: Nwamaka Umeweni
Communications manager: Shalu Kanal
Project manager:

Jeremy Powell

Consultees

Manufacturers/sponsors
  • Amgen (darbepoetin alfa, Aranesp)
  • Hospira (epoetin zeta, Retacrit)
  • Janssen-Cilag (epoetin alfa, Eprex)
  • Roche Products (epoetin beta, NeoRecormon)
  • Sandoz (epoetin alfa, Binocrit)
Patient/carer groups
  • Leukaemia Cancer Society
  • Leukaemia CARE
  • Myeloma UK
  • Target Ovarian Cancer
Professional groups
  • British Society for Haematology
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
Others
  • Department of Health
  • NHS England
  • Welsh Assembly Government

Commentators

General
  • Commissioning Support Appraisals Service
  • Department of Health,Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Hospital Information Services (Jehovah’s Witnesses)
  • Medicines and Healthcare products Regulatory Agency
Comparator manufacturers
  • None
Relevant research groups
  • Cochrane Haematological Malignancies Group
  • MRC Clinical Trials Unit
Assessment Group
  • Peninsula Technology Assessment Group, University of Exeter
Associated guideline groups
  • National Collaborating Centre for Cancer
Get involved